Entasis Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Entasis Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C2807
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Entasis Therapeutics Inc (Entasis) is a drug development company that discovers and develops anti-infective therapies for drug-resistant bacterial infections. The company’s pipeline products include ETX2514, ETX0282, ETX0914 and Zoliflodacin. Its ETX2514 is a potent inhibitor of class A, C, and D beta-lactamases intended to treat serious gram-negative infections. Entasis’ ETX0914, is an oral antibiotic for the treatment of uncomplicated gonorrhoea. The company’s pipeline products are used to treat multidrug-resistant gram-negative infections such as pseudomonas aeruginosa, acinetobacter baumanii, carbapenem-resistant enterobacteriaceae, and neisseria gonorrhoeae, among others. It also develops robust clinical and pre-clinical pipeline of medicines. Entasis is headquartered in Waltham, Massachusetts, the US.

Entasis Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Entasis Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Entasis Therapeutics Raises Additional USD32 Million in Series B-1 Financing 11
Entasis Therapeutics Raises USD50 Million in Series B Financing 13
Entasis Therapeutics Raises USD40 Million in Series A Venture Financing 14
Partnerships 15
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 15
Licensing Agreements 16
Zai Lab Enters into Licensing Agreement with Entasis Therapeutics 16
Entasis Therapeutics Inc – Key Competitors 17
Entasis Therapeutics Inc – Key Employees 18
Entasis Therapeutics Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Corporate Communications 20
May 01, 2018: Entasis Therapeutics Appoints David C. Hastings to Board of Directors 20
Apr 10, 2017: Entasis Appoints Mike Gutch as Chief Financial Officer and Chief Business Officer 21
Product News 22
06/30/2017: Entasis Publishes Data Highlighting the Potent and Differentiated Activity of ETX2514 Combinations against Drug Resistant Gram-negative Bacteria Including Acinetobacter and Pseudomonas 22
06/07/2017: Entasis Therapeutics Presents Data on ETX2514 at ASM Microbe 2017 23
05/22/2017: Entasis Therapeutics to Present Data on ETX0282 at ASM Microbe 2017 24
05/22/2017: Entasis Therapeutics to Present Data on ETX1317 at ASM Microbe 2017 25
05/22/2017: Entasis Therapeutics to Present Data on ETX2514 at ASM Microbe 2017 26
Clinical Trials 27
Oct 09, 2017: Entasis Therapeutics Highlights Positive Phase 1 Data for ETX2514 at IDWeek 2017, Announces Plans to Advance Combination with sulbactam (ETX2514SUL) into Phase 2 Trials 27
Sep 28, 2017: Entasis Therapeutics to Present Phase 1 Data on ETX2514 at IDWeek 2017 28
Apr 21, 2017: Entasis Therapeutics to Present Data on ETX2514SUL at 27th European Congress of Clinical Microbiology and Infectious Diseases 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Entasis Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Entasis Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Entasis Therapeutics Raises Additional USD32 Million in Series B-1 Financing 11
Entasis Therapeutics Raises USD50 Million in Series B Financing 13
Entasis Therapeutics Raises USD40 Million in Series A Venture Financing 14
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 15
Zai Lab Enters into Licensing Agreement with Entasis Therapeutics 16
Entasis Therapeutics Inc, Key Competitors 17
Entasis Therapeutics Inc, Key Employees 18

List of Figures
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Entasis Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Entasis Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • FleetPride, Inc.:企業のM&A・事業提携・投資動向
    FleetPride, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's FleetPride, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Pelago Bioscience AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Pelago Bioscience AB (Pelago Bioscience) is a developer of patented cellular thermal shift assay for use in determination and quantification of drug–target interactions. The company utilizes patented CETSA technology which enables direct, in situ physiologically relevant measurements of targ …
  • Jyoti Structures Ltd (JYOTISTRUC)-エネルギー分野:企業M&A・提携分析
    Summary Jyoti Structures Ltd (JSL) is a turnkey engineering, procurement, and construction (EPC) services provider that designs, tests, manufactures, sources, constructs, and supplies transmission lines, substations, and microwave towers. It designs HVDC and river crossing transmission towers, subst …
  • KT Corporation:企業のM&A・事業提携・投資動向
    KT Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's KT Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Systematic A/S:企業の戦略・SWOT・財務分析
    Systematic A/S - Strategy, SWOT and Corporate Finance Report Summary Systematic A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Essar Power Ltd:企業の戦略的SWOT分析
    Essar Power Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Celanese Corporation:企業の戦略・SWOT・財務情報
    Celanese Corporation - Strategy, SWOT and Corporate Finance Report Summary Celanese Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Ecobee Inc:電力:M&Aディール及び事業提携情報
    Summary Ecobee Inc (Ecobee) is a thermostat device provider. The company offers ecobee swith plus, ecobee four, ecobee four smarter bundle, ecobee three lite, ecobee three lite smarter bundle, refurbished ecobee three, EMS Si and room sensors. Its products are controlled through voice control and mo …
  • Press Ganey Associates Inc:企業の戦略的SWOT分析
    Press Ganey Associates Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Beximco Pharmaceuticals Ltd (BXPHARMA):企業の財務・戦略的SWOT分析
    Summary Beximco Pharmaceuticals Ltd (Beximco Pharma) is a manufacturer and exporter of generic medicines and active pharmaceutical ingredients (APIs). The company offers products in the therapeutic areas of allergic disorders, analgesics and antipyretic, anti-infectives, cardiovascular, central nerv …
  • United-Guardian Inc (UG):企業の財務・戦略的SWOT分析
    Summary United-Guardian Inc (United-Guardian) is a diversified company that manufactures and markets healthcare products. The company offers pharmaceuticals, cosmetic ingredients, health care products and proprietary industrial products, among others. It provides medical devices such as lubrajel flu …
  • Webjet Limited:企業の戦略・SWOT・財務情報
    Webjet Limited - Strategy, SWOT and Corporate Finance Report Summary Webjet Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • SunPower Corporation (SPWR)-エネルギー分野:企業M&A・提携分析
    Summary SunPower Corporation (SunPower), a subsidiary of Total Energies Nouvelles Activites USA, is a provider of solar technology and energy services. The company has a presence in solar value chain from cell and panel manufacturing, project development, project finance through engineering, procure …
  • MORRE-TEC Industries, Inc.:戦略・SWOT・企業財務分析
    MORRE-TEC Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary MORRE-TEC Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • CASI Pharmaceuticals Inc (CASI):製薬・医療:M&Aディール及び事業提携情報
    Summary CASI Pharmaceuticals Inc (CASI) is a biopharmaceutical company, which focuses on the acquisition, development and commercialization of innovative therapies for treating cancer and other unmet medical needs. Its pipeline product portfolio includes ENMD-2076 that is being developed globally fo …
  • The Brookwood Partnership Ltd:企業の戦略・SWOT・財務情報
    The Brookwood Partnership Ltd - Strategy, SWOT and Corporate Finance Report Summary The Brookwood Partnership Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Korean Air Lines Co Ltd
    Korean Air Lines Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Korean Air Lines Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • APRIL Group S.A. (APR):企業の財務・戦略的SWOT分析
    APRIL Group S.A. (APR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Albumedix AS-製薬・医療分野:企業M&A・提携分析
    Summary Albumedix A/S (Albumedix), a subsidiary of Novozymes A/S, is a developer of albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery. Its product Recombumin is a recombinant human albumin used in the manufacture of …
  • Total Brain Ltd (TTB):企業の財務・戦略的SWOT分析
    Summary Total Brain Ltd (TBL) formerly, Brain Resource Ltd is a healthcare service provider that offers therapies. The company carries out research and development of brain products. TBL’s products comprise iSPOT, Total Brain and MyBrainSolutions. The company’s Total Brain is a brain health solution …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆